Jacqueline E. Shea Ph.D.
Net Worth

Last updated:

What is Jacqueline E. Shea Ph.D. net worth?

The estimated net worth of Dr. Jacqueline E. Shea Ph.D. is at least $4,002,853 as of 15 May 2024. He owns shares worth $41,457 as insider, has earned $774,796 from insider trading and has received compensation worth at least $3,186,600 in Inovio Pharmaceuticals, Inc..

What is the salary of Jacqueline E. Shea Ph.D.?

Dr. Jacqueline E. Shea Ph.D. salary is $637,320 per year as Chief Operating Officer in Inovio Pharmaceuticals, Inc..

How old is Jacqueline E. Shea Ph.D.?

Dr. Jacqueline E. Shea Ph.D. is 59 years old, born in 1966.

What stocks does Jacqueline E. Shea Ph.D. currently own?

As insider, Dr. Jacqueline E. Shea Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Inovio Pharmaceuticals, Inc. (INO) Chief Operating Officer 21,592 $1.92 $41,457

What does Inovio Pharmaceuticals, Inc. do?

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

INO logo
INO
Inovio Pharmaceuticals, Inc.
$1.92

Jacqueline E. Shea Ph.D. insider trading

Inovio Pharmaceuticals, Inc.

Dr. Jacqueline E. Shea Ph.D. has made 7 insider trades between 2020-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 66,000 units of INO stock on 10 May 2023. As of 15 May 2024 he still owns at least 21,592 units of INO stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 17,745 N/A N/A
Option
Restricted Stock Unit 17,745 N/A N/A
Option
Common Stock 5,500 N/A N/A
Option
Restricted Stock Unit 5,500 N/A N/A
Option
Common Stock 1,878 N/A N/A
Option
Restricted Stock Unit 1,878 N/A N/A
Option
Restricted Stock Unit 5,853 N/A N/A
Option
Common Stock 5,853 N/A N/A
Option
Restricted Stock Unit 66,000 N/A N/A
Option
Common Stock 66,000 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 16,666 N/A N/A
Option
Restricted Stock Unit 16,666 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 59,737 N/A N/A
Option
Common Stock 22,545 N/A N/A
Option
Restricted Stock Unit 22,545 N/A N/A
Sale
Common Stock 38,535 N/A N/A
Sale
Common Stock 4,710 N/A N/A
Option
Common Stock 16,667 N/A N/A
Option
Restricted Stock Unit 16,667 N/A N/A
Sale
Common Stock 16,881 $10.06 $169,823
Option
Common Stock 59,737 N/A N/A
Option
Restricted Stock Unit 59,737 N/A N/A
Option
Common Stock 22,376 N/A N/A
Option
Common Stock Option 22,376 $3.62 $81,001
Sale
Common Stock 28,336 $7.5 $212,520
Option
Common Stock 55,248 $3.62 $199,998
Sale
Common Stock 16,713 N/A N/A
Option
Common Stock Option 55,248 $3.62 $199,998
Option
Common Stock 22,376 N/A N/A
Sale
Common Stock 28,336 $7.83 $221,871
Sale
Common Stock 28,336 $6.02 $170,583
Option
Common Stock Option 22,376 N/A N/A
Option
Restricted Stock Unit 16,667 N/A N/A
Option
Common Stock 16,667 N/A N/A

Inovio Pharmaceuticals key executives

Inovio Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: